Related Experiment Video
Updated: May 14, 2026
Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
Published on: February 11, 2019
Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease
Yoshinobu Aisa1, Takehiko Mori, Jun Kato
1Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Insights
The NIH consensus criteria effectively classify chronic graft-versus-host disease (GVHD) subtypes. However, these criteria show limited ability to predict transplant outcomes, necessitating further research for refinement.
Area of Science:
- Hematology
- Immunology
- Transplantation Medicine
Background:
- Graft-versus-host disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation.
- Accurate classification and severity grading of chronic GVHD are crucial for patient management and outcome prediction.
- The National Institutes of Health (NIH) consensus criteria provide a framework for diagnosing and classifying chronic GVHD.
Purpose of the Study:
- To validate the utility of the NIH consensus criteria for classifying chronic GVHD.
- To assess the correlation between chronic GVHD subtypes and severity with transplant outcomes.
- To determine the prognostic significance of the NIH criteria in patients undergoing allogeneic stem cell transplantation.
Main Methods:
- Retrospective review of 143 patients who developed GVHD more than 100 days post-transplant.
- Reclassification of GVHD into subtypes (late acute GVHD, classic chronic GVHD, overlap syndrome) and severity grading using NIH criteria.
- Statistical analysis to compare outcomes between different GVHD subtypes and severity grades.
Main Results:
- The NIH criteria successfully reclassified 97.2% of patients.
- Overlap syndrome was associated with significantly higher rates of moderate and severe disease compared to classic chronic GVHD.
- Neither GVHD subtype nor severity grading using NIH criteria demonstrated significant prognostic value for transplant-related mortality, survival, or immunosuppressant discontinuation.
Conclusions:
- The NIH consensus criteria are valuable for classifying chronic GVHD subtypes.
- The criteria have limited predictive power for clinical outcomes in allogeneic stem cell transplantation.
- Further prospective studies are needed to refine the NIH criteria for improved prognostic accuracy.
Abstract:
To validate the National Institutes of Health (NIH) consensus criteria for chronic GVHD, we retrospectively reviewed 143 patients who developed GVHD later than 100 days after allogeneic hematopoietic stem cell transplantation. Their GVHD was reclassified and the severity was graded according to the criteria. Only four patients (2.8 %) could not be reclassified into any type of GVHD. In the remaining 139 patients, reclassified subtypes were late acute GVHD in 52 patients (37.4 %), classic chronic GVHD in 33 (23.7 %), and overlap syndrome in 54 (38.8 %). Of 87 patients with classic chronic GVHD or overlap syndrome, the severity was graded as mild in 21 patients (24 %), moderate in 53 (61 %), and severe in 13 (15 %). The proportions of moderate (70 %) and severe (20 %) disease were significantly higher in patients with overlap syndrome than those with classic chronic GVHD (46 and 6 %, respectively; P < 0.001). Univariate and multivariate analyses of subtypes and severity did not identify any significant prognostic values in any of the transplant outcomes, such as transplant-related mortality, overall survival, GVHD-specific survival, or discontinuation of systemic immunosuppressants. These findings suggest that the NIH consensus criteria are useful for classification of chronic GVHD, but have limited significance in predicting clinical outcomes. The validity of these criteria remains inconclusive, and future prospective studies will be required to refine them.
Related Concept Videos
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:26Nephrotic Syndrome II : Assessment and Medical Management